ENGN — enGene Therapeutics Share News
0.000.00%
Last trade - 00:00- $117.23m
- -$116.13m
enGene Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Engene Holdings Inc - To Change Name To Engene Therapeutics Inc. Effective April 8, 2026
Brief: Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common Shares
Brief: enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Brief: Engene Holdings Files For Mixed Shelf Of Upto $400 Million
Brief: Engene Announces Expanded $125 Million Debt Facility With Hercules Capital, Inc.
Brief: Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness
Brief: Engene Holdings Prices 12,558,823 Common Shares At $8.50 Per Share
Brief: enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing
Brief: enGene Announces Proposed Public Offering Of Common Shares
Brief: Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months
Brief: enGene Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: FDA Grants RMAT Designation for enGene’s Detalimogene
enGene Holdings Inc reports results for the quarter ended April 30 - Earnings Summary
Brief: enGene Reports Second Quarter 2025 Financial Results And Provides Business Update
enGene Holdings Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: enGene Names Amy Pott As Chief Global Commercialization Officer
Brief: Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)